Merck’s MRK stock has declined around 10.3% in the past three months, losing almost $32 billion of its market value. Merck ...

Merck (MRK) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of ...

Merck (NYSE: MRK) stock has been a longtime winner for investors, returning 72% in the past five years. A major factor in ...

Daiichi Sankyo and Merck said on Tuesday that their drug, patritumab deruxtecan, met the main goal of extending the time some ...

Charlie CY Yang, an analyst from Bank of America Securities, maintained the Buy rating on Merck & Company (MRK – Research Report).

A U.S. appeals court on Friday revived more than 500 lawsuits alleging that Merck & Co failed to warn that its osteoporosis ...

Collis, David J. "Strategy in the Twenty-First Century Pharmaceutical Industry: Merck & Co. and Pfizer Inc. (TN)." Harvard Business School Teaching Note 713-450, March 2013.

5, 2024 /CNW/ - Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced that it has successfully completed negotiations with the pan-Canadian Pharmaceutical Alliance (pCPA) ...

Stocks of medical tools supplier Precision System Science jumped 67.1% last month, vaccine manufacturer Bavarian Nordic ...

Detailed price information for Merck & Company (MRK-N) from The Globe and Mail including charting and trades.